昂利康：获得西格列汀二甲双胍缓释片药品注册证书

Core Viewpoint - The company has received the drug registration certificate for the combination drug Sitagliptin Metformin Extended-Release Tablets from the National Medical Products Administration, which is intended for adult patients with type 2 diabetes currently undergoing treatment with both Sitagliptin and Metformin Extended-Release Tablets [1] Group 1 - The drug is a compound formulation suitable for adult patients with type 2 diabetes [1] - The company received the drug marketing license application acceptance notice in January 2024 and has recently obtained approval from the National Medical Products Administration [1] - The approval of the drug registration certificate is considered equivalent to passing the consistency evaluation, which will further enrich the company's product pipeline [1] Group 2 - There is significant uncertainty regarding the specific sales performance of the newly approved drug [1]